Comparative Analysis of Pupil Diameters in Light and Dark Conditions After Instillation of 0.15% Brimonidine Drops in Eyes With and Without Pseudoexfoliation Syndrome

Overview

Journal Beyoglu Eye J

Publisher Kare Publishing

Specialty Ophthalmology

Date 2022 Jan 31

PMID 35098090

Authors

Sercan Cate

Caglar Bektas

Burak Turgut

Affiliations

Soon will be listed here.

Abstract

Objectives: This study aimed to compare pupil diameters in light and dark conditions after instillation of 0.15% brimonidine drops in eyes with and without pseudoexfoliation syndrome (PES).

Methods: Forty eyes of 40 patients in whom 0.15% brimonidine drops were instilled to their right eyes between March 2019 and June 2019 were analyzed in this study. Study groups included 20 subjects without PES (group 1) and 20 patients with PES (group 2). Pupil diameters before and 30 and 90 min after brimonidine application were recorded and analyzed.

Results: In group 1, the mean pupil diameters before brimonidine drop instillation were 4.8±1.2 mm and 5.8±1.2 mm in light and dark conditions, respectively, while those in group 2 were 4.4±1.2 mm and 4.9±1.3 mm, respectively. At 30 min after brimonidine drop instillation, the pupil diameters in light and dark conditions were 4.3±1.1 mm and 5.3±1.0 mm in group 1 and 4.1±1.1 mm and 4.5±1 mm in group 2, respectively. In group 1, the mean pupil diameters at 90 min were 4.2±1.1 mm and 5.1±1.1 mm in light and dark, respectively, and in group 2, they were 4.0±1.1 mm and 4.4±1.2 mm, respectively. In the dark, the pupil diameters before drop instillation were significantly smaller in group 2 than in group 1 (p≤0.05). A significant difference was found between the groups with respect to the measurements in the dark at 30 min (p≤0.05). When the differences at 30 and 90 min and the initial pupil diameters in light condition were compared between the groups, the change in the pupil diameter at 30 min was statistically significant (p≤0.05). At 90 min, differences in both light and dark measurements were statistically significant (p≤0.05).

Conclusion: Brimonidine causes significant miosis in eyes with PES compared with eyes without PES. Brimonidine may have positive effects on spherical aberrations, glares, and halos. However, inadequate pupillary dilation may make it more difficult to perform cataract surgery and may further increase the complication rate.

Citing Articles

Effects of brimonidine tartrate 0.2 and 0.15% ophthalmic solution on the static and dynamic pupil characteristics.

Yang J, Zhang X, Zhong M, Bai Y, Liu W, Hu J Front Med (Lausanne). 2023; 10:1160414.

PMID: 37256086 PMC: 10225522. DOI: 10.3389/fmed.2023.1160414.

References

Martinez C, Applegate R, Klyce S, McDonald M, Medina J, Howland H . Effect of pupillary dilation on corneal optical aberrations after photorefractive keratectomy. Arch Ophthalmol. 1998; 116(8):1053-62. DOI: 10.1001/archopht.116.8.1053. View

Ahmed F, Hegazy K, Chaudhary P, Sharma S . Neuroprotective effect of alpha(2) agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure. Brain Res. 2001; 913(2):133-9. DOI: 10.1016/s0006-8993(01)02759-7. View

Ritch R . Ocular Findings in Exfoliation Syndrome. J Glaucoma. 2018; 27 Suppl 1:S67-S71. DOI: 10.1097/IJG.0000000000000986. View

Shemesh G, Moisseiev E, Lazar M, Kesler A . Effect of brimonidine tartrate 0.10% ophthalmic solution on pupil diameter. J Cataract Refract Surg. 2011; 37(3):486-9. DOI: 10.1016/j.jcrs.2010.09.026. View

Sangal N, Chen T . Cataract surgery in pseudoexfoliation syndrome. Semin Ophthalmol. 2014; 29(5-6):403-8. DOI: 10.3109/08820538.2014.959189. View

LeBlanc R . Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. Ophthalmology. 1998; 105(10):1960-7. DOI: 10.1016/s0161-6420(98)91048-x. View

Galanopoulos A, Goldberg I . Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension. Clin Ophthalmol. 2009; 3:117-22. PMC: 2709013. View

Tekin K, Sekeroglu M, Kiziltoprak H, Yetkin E, Doguizi S, Yilmazbas P . Static and Dynamic Pupillary Characteristics in Clinically Unilateral Pseudoexfoliation Syndrome. J Glaucoma. 2018; 27(6):552-557. DOI: 10.1097/IJG.0000000000000953. View

Li J, Miller J, Florakis G . Night vision disturbances after corneal refractive surgery. Surv Ophthalmol. 2002; 47(6):533-46. DOI: 10.1016/s0039-6257(02)00350-8. View

10.

McDonald 2nd J, El-Moatassem Kotb A, Decker B . Effect of brimonidine tartrate ophthalmic solution 0.2% on pupil size in normal eyes under different luminance conditions. J Cataract Refract Surg. 2001; 27(4):560-4. DOI: 10.1016/s0886-3350(01)00769-6. View

11.

Vidal-Sanz M, Lafuente M, Mayor-Torroglosa S, Aguilera M, de Imperial J, Villegas-Perez M . Brimonidine's neuroprotective effects against transient ischaemia-induced retinal ganglion cell death. Eur J Ophthalmol. 2001; 11 Suppl 2:S36-40. DOI: 10.1177/112067210101102S04. View

12.

Repo L, Naukkarinen A, Paljarvi L, Terasvirta M . Pseudoexfoliation syndrome with poorly dilating pupil: a light and electron microscopic study of the sphincter area. Graefes Arch Clin Exp Ophthalmol. 1996; 234(3):171-6. DOI: 10.1007/BF00462029. View

13.

Fontana L, Coassin M, Iovieno A, Moramarco A, Cimino L . Cataract surgery in patients with pseudoex-foliation syndrome: current updates. Clin Ophthalmol. 2017; 11:1377-1383. PMC: 5546806. DOI: 10.2147/OPTH.S142870. View

14.

Tekin K, Kiziltoprak H, Sekeroglu M, Yetkin E, Bayraktar S, Yilmazbas P . Static and dynamic pupil characteristics in pseudoexfoliation syndrome and glaucoma. Clin Exp Optom. 2019; 103(3):332-338. DOI: 10.1111/cxo.12945. View

15.

Kivela T . Histopathology of Exfoliation Syndrome. J Glaucoma. 2018; 27 Suppl 1:S38-S43. DOI: 10.1097/IJG.0000000000000947. View

16.

Kato C, Shimizu K, Kamiya K, Ishikawa H, Igarashi A . Effects of brimonidine tartrate 0.1% ophthalmic solution on the pupil, refraction, and light reflex. Sci Rep. 2018; 8(1):9003. PMC: 5998017. DOI: 10.1038/s41598-018-27436-8. View

17.

Thordsen J, Bower K, Warren B, Stutzman R . Miotic effect of brimonidine tartrate 0.15% ophthalmic solution in normal eyes. J Cataract Refract Surg. 2004; 30(8):1702-6. DOI: 10.1016/j.jcrs.2003.12.037. View

18.

Jeng S, Karger R, Hodge D, Burke J, Johnson D, Good M . The risk of glaucoma in pseudoexfoliation syndrome. J Glaucoma. 2007; 16(1):117-21. DOI: 10.1097/01.ijg.0000243470.13343.8b. View

19.

Edwards J, Burka J, Bower K, Stutzman R, Sediq D, Rabin J . Effect of brimonidine tartrate 0.15% on night-vision difficulty and contrast testing after refractive surgery. J Cataract Refract Surg. 2008; 34(9):1538-41. DOI: 10.1016/j.jcrs.2008.05.029. View

20.

Kesler A, Shemesh G, Rothkoff L, Lazar M . Effect of brimonidine tartrate 0.2% ophthalmic solution on pupil size. J Cataract Refract Surg. 2004; 30(8):1707-10. DOI: 10.1016/j.jcrs.2004.02.043. View